Inhibikase Therapeutics (IKT) Insider Canner Buys 155,000 Shares
Insider activity at Inhibikase Therapeutics, Inc. as David Canner picks up 155,000 shares.
Reviewed by automated data checks against the source filing. How we make and check alerts
David Canner bought 155,000 shares of Inhibikase Therapeutics, Inc. ($IKT) on June 26, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $IKT is up 3.7% after 1 week, up 23.0% after 1 month and down 13.6% to date (from the $1.91 close on Jun 26, 2026).
IKT
Inhibikase Therapeutics, Inc.
Key Points
- David Canner purchased 155,000 shares of Inhibikase Therapeutics, Inc. (NasdaqCM: IKT) on June 26, 2026.
- The stock traded at $2.03 per share around the time of the recent insider transaction.
- Chardan Capital recently initiated coverage on the biotechnology company with a Neutral rating and a $1.50 price target.
Get $IKT trade alerts by text
We text you when insiders, Congress or big funds trade $IKT. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Inhibikase Therapeutics, Inc. alert may contain errors. Disclosures
David Canner Buys Inhibikase Therapeutics, Inc. Shares
David Canner picked up 155,000 shares of Inhibikase Therapeutics, Inc. (NasdaqCM: IKT) in a transaction dated June 26, 2026. This purchase brings fresh insider attention to the biotechnology firm as stakeholders navigate ongoing clinical developments.
Inhibikase Therapeutics, Inc. Stock Performance
Shares of Inhibikase Therapeutics traded at $2.03 on Wednesday, sitting between its 52-week low of $1.33 and its 52-week high of $2.61. The stock currently rests near its 200-day moving average of $1.92, while holding slightly below its 50-day moving average of $2.34.
Analysts Set New Price Targets
Wall Street firms continue to monitor the clinical-stage drug developer. On October 13, 2026, Chardan Capital initiated coverage on the stock with a Neutral rating and a $1.50 price target. Overall, the company maintains a strong buy consensus from nine analysts, with a mean target price of $6.00.
Inside Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company based in Wilmington, Delaware. The firm develops treatments to modify cardiopulmonary diseases, focusing primarily on pulmonary arterial hypertension with its lead candidate IKT-001. The company has 35 employees and carries a market capitalization of roughly $307.0 million.
What to Watch Next for Inhibikase Therapeutics, Inc.
Investors will look toward upcoming pipeline updates and the company's next scheduled earnings report on November 13, 2026. Additional Form 4 filings will provide further clarity on insider sentiment as clinical trials progress.
Related Filing Alerts
Source: David Canner's Form 4 filing on $IKT (Jun 26, 2026). Find the original filing: IKT Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts